Suggest a research topic for a multicenter randomized trial of adjunctive corticosteroids versus placebo in non‑HIV immunocompromised adults with severe Pneumocystis jirovecii pneumonia receiving trimethoprim‑sulfamethoxazole.

Research Topic: Adjunctive Corticosteroids in Non-HIV Immunocompromised Adults with Severe Pneumocystis jirovecii Pneumonia

Proposed Multicenter Randomized Controlled Trial

A multicenter, double-blind, randomized placebo-controlled trial evaluating adjunctive corticosteroids versus placebo in non-HIV immunocompromised adults with severe Pneumocystis jirovecii pneumonia receiving trimethoprim-sulfamethoxazole is critically needed, as current evidence remains conflicting and the most recent high-quality trial showed no significant mortality benefit.

Rationale for This Research Topic

Current Evidence Gap

• The most recent multicenter RCT (2025) in France enrolled 218 non-HIV patients with PJP and acute respiratory failure, finding no significant reduction in 28-day mortality with adjunctive methylprednisolone (32.4% placebo vs 21.5% corticosteroids; p=0.069) 1

• Historical evidence from HIV-infected patients demonstrates clear benefit from adjunctive corticosteroids for severe PCP, but this evidence cannot be directly extrapolated to non-HIV populations 2

• Observational data from Japan (2019) involving 1,299 non-HIV PJP patients showed adjunctive corticosteroids reduced 60-day mortality in severe cases (PaO2 ≤60 mmHg) with mortality rates of 24.7% versus 36.6% (p=0.006) 3

• A Mayo Clinic retrospective study (2018) of 323 non-HIV patients found early corticosteroids were NOT associated with improved respiratory outcomes or mortality 4

Key Controversies Requiring Resolution

The fundamental question remains whether corticosteroids provide mortality benefit in non-HIV immunocompromised patients with severe PJP, as the pathophysiology differs substantially from HIV-related PJP 1, 3, 4

• Non-HIV PJP progresses more rapidly with higher baseline mortality (30-60%) compared to HIV-related disease 1, 5

• The 2025 French trial was underpowered at the severe disease stratum, with most patients (95%) requiring ICU or intermediate care 1

• Subgroup analyses suggest potential harm in patients without shock, raising concerns about indiscriminate corticosteroid use 6

Proposed Trial Design Elements

Population Specification

Target enrollment: Non-HIV immunocompromised adults with:

• Microbiologically confirmed PJP (PCR, immunofluorescence, or mNGS from BAL) 1, 5
• Severe hypoxemia defined as PaO2 ≤60 mmHg or PaO2/FiO2 ratio <200 1, 3
• Anti-Pneumocystis treatment duration <7 days at enrollment 1
• Age ≥18 years requiring ICU admission or high-flow oxygen 1

Intervention Arms

Corticosteroid arm: Methylprednisolone IV 30 mg twice daily (days 1-5), 30 mg once daily (days 6-10), 20 mg once daily (days 11-21) 1

Placebo arm: Matching isotonic saline injections with identical administration schedule 1

Both arms receive: Trimethoprim-sulfamethoxazole at TMP 15-20 mg/kg/day as standard therapy 7, 8

Stratification Factors

• Underlying immunosuppression type: Solid organ transplant versus hematologic malignancy versus other immunosuppression 2, 9
• Baseline oxygen requirement: <6 L/min versus ≥6 L/min 1
• Presence of septic shock at enrollment (critical given subgroup findings) 6
• Concurrent long-term corticosteroid use (>1 month prior to enrollment) 1

Primary Outcome

All-cause mortality at 60 days (rather than 28 days, given the prolonged disease course in non-HIV patients) 3, 6

Key Secondary Outcomes

• Respiratory failure progression: Change in Sequential Organ Failure Assessment respiratory component (SOFAresp) at days 5,10, and 14 4
• Need for mechanical ventilation and duration 1, 4
• ICU-free days at 60 days 1
• Time to clinical stability (fever resolution, oxygen independence) 8
• Hospital length of stay 1, 4

Critical Safety Outcomes

• Secondary infections (bacterial, fungal, viral) occurring during treatment 2, 1
• Hyperglycemia requiring insulin therapy 2, 1
• Gastrointestinal bleeding 2
• Invasive aspergillosis (particularly relevant in this population) 2

Specific Methodological Considerations

Sample Size Justification

Based on the 2025 French trial showing 10.9% absolute mortality difference (32.4% vs 21.5%), a properly powered trial would require approximately 350-400 patients per arm to detect this difference with 80% power and alpha of 0.05 1

Subgroup Analyses (Pre-specified)

• Effect modification by presence of septic shock at baseline (given conflicting observational data) 6
• Effect modification by underlying disease: solid organ transplant recipients versus hematologic malignancy versus autoimmune disease 2, 9
• Effect modification by baseline PaO2/FiO2 ratio (<100 vs 100-200) 1, 3
• Effect modification by time from symptom onset to treatment initiation 1

Infection Surveillance Protocol

Given the high risk of secondary infections in this population receiving both immunosuppression and potential corticosteroids:

• Systematic screening for bacterial, fungal (including Aspergillus galactomannan), and viral pathogens at baseline, day 7, and day 14 2
• Prophylactic antimicrobials per institutional protocols (document and analyze as covariate) 2
• Mandatory infectious disease consultation for all enrolled patients 2

Clinical Equipoise Justification

The most recent high-quality RCT showed a non-significant trend toward benefit (p=0.069), while observational data remain conflicting 1, 3, 4, 6

• The 2025 French trial was likely underpowered for the severe disease subgroup where benefit might exist 1
• Observational studies suggest potential benefit in severe disease but possible harm in less severe cases 3, 6
• Current guidelines for non-HIV PJP do not provide clear recommendations on adjunctive corticosteroids, unlike the strong recommendation for HIV-related severe PCP 2

Potential Impact

This trial would definitively answer whether adjunctive corticosteroids reduce mortality in non-HIV immunocompromised adults with severe PJP, potentially changing practice for thousands of patients annually who face 30-60% mortality rates 1, 5

• If positive, would establish corticosteroids as standard of care for this high-mortality condition 1, 3
• If negative or showing harm in specific subgroups, would prevent inappropriate corticosteroid use and associated complications 4, 6
• Would provide critical data on optimal patient selection for adjunctive therapy based on disease severity and underlying immunosuppression 3, 6